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METHODS FOR STEM CELL PRODUCTION 
AND THERAPY 
CROSS REFERENCE TO RELATED 
APPLICATIONS 
This application claims the benefit of the filing date of U.S. 
Provisional Patent Application No. 61/069,886, filed Mar. 18, 
2008, and U.S. Provisional Patent Application No. 61/136, 
496, filed Sep. 9, 2008, which are each incorporated herein by 
reference in its entirety. 
STATEMENT REGARDING 
FEDERALLY-SPONSORED RESEARCH AND 
DEVELOPMENT 
Statement under MPEP 310. The U.S. government has a 
paid-up license in this invention and the right in limited cir-
cumstances to require the patent owner to license others on 
reasonable terms as provided for by the terms of NASA West 
Virginia Space Grant Consortium Agreement No. 
NNG05GF80H, awarded by the National Aeronautics and 
Space Administration (NASA). 
Part of the work performed during development of this 
invention utilized U.S. Government funds. The U.S. Govern-
ment has certain rights in this invention. 
NAMES OF THE PARTIES TO A JOINT 
RESEARCH AGREEMENT 
Not applicable. 
BACKGROUND OF THE INVENTION 
1. Field of the Invention 
The present invention relates to methods for culturing stem 
cells in modeled microgravity conditions, including embry-
onic, adult, multipotent hematopoietic progenitor cells and 
cancer stem cells. The present invention also relates to meth-
ods for proliferating stem cells by culturing stem cells, 
including embryonic, adult, multipotent hematopoietic pro-
genitor cells and cancer stem cells, under conditions of micro-
gravity. The current invention also relates to methods for 
increasing telomerase activity and telomere length. Further-
more, the current invention relates to methods for culturing 
cancer stem cells under microgravity conditions thereby 
increasing their susceptibility to chemotherapeutic agents. 
The present invention also relates to methods for mass pro-
ducing cellular factors by culturing stem cells under condi-
tions of microgravity. Additionally, the current invention 
relates to a method for improving the treatment outcome of 
cancer in a mammal by subjecting the mammal to simulated 
microgravity followed by administering a chemotherapeutic 
agent to the mammal. The current invention also relates to a 
method for testing effectiveness of chemotherapy drugs on 
cancer stem cells. 
2. Background Art 
Stem cells show potential for many different areas of health 
and medical research. Some of the most serious medical 
conditions, such as cancer and birth defects, are caused by 
problems that occur somewhere in the process of stem cell 
differentiation or maintenance. Broadly, there are two differ-
ent types of stem cells, embryonic stem cells and adult stem 
cells. Embryonic stem cells are found in blastocysts and have 
the ability to differentiate into all of the specialized embry-
onic tissues. Adult stem cells are undifferentiated cells found 
throughout the body after embryonic development. Adult 
stem cells are able to divide and replenish dying cells and 
regenerate damaged tissue. Furthermore, adult stem cells can 
maintain the normal turnover of regenerative organs such as 
blood, skin and intestinal tissue. Adult stem cells have the 
5 ability to divide and self-renew indefinitely and are able to 
generate all of the cell types of the organ from which they 
originate. 
Stem cells can be classified as being totipotent, pluripotent, 
multipotent or unipotent based on their potential to differen- 
io tiate into different cell types. Totipotent stem cells are pro-
duced from the fusion of gametes and the first few divisions of 
the fertilized egg. These cells can differentiate into embryonic 
and extraembryonic cell types. Pluripotent stem cells can 
differentiate into cells from any of the three germ layers. 
15 Multipotent calls can produce only cells of a closely related 
family. Unppotent cells can produce only one cell type, but 
have the property of self-renewal which distinguishes them 
from non-stem cells. Most adult stem cells are lineage 
restricted multipotent stem cells, and are referred to by their 
20 tissue of origin. Pluripotent adult stem cells are rare and 
generally small in number but can be found in a number of 
tissues including umbilical cord blood (Ratajczak M. Z., et 
al., Leukemia 21(5): 860-867 (2007)). There are several dif-
ferent types of adult stem cells including, but not limited to, 
25 adipose derived stem cells (Zuk, P. A., et al., Tissue Engineer-
ing 7:211-216) (2001)), epithelial stem cells, hematopoietic 
stem cells, mammary stem cells (Shackleton, M., et al., 
Breast Cancer R E. 7:86-95 (2005)), mesenchymal stem 
cells, endothelial stem cells, neural stem cells (Alvarez- 
3o Bullta, A., et al., Brain Res. Bull. 57:751-758 (2002)), olfac-
tory stem cells (Murrel, W., et al., Deu Dyn. 233:496-515 
(2005)), testicular stem cells, dental pulp derived stem cells, 
and umbilical cord blood hematopoietic progenitor cells. 
When an adult stem cell divides, it creates another cell like 
35 itself and a cell more differentiated than itself. This process of 
asymmetric cell division, gives rise to one identical daughter 
cell and one early transient-amplifying cell (early TA), which 
possesses high proliferative capacity. Through a series of cell 
divisions, the early TA cell gives rise to a late TA cell followed 
4o by a tissue-specific progenitor cell and finally to the bulk of 
differentiated cells that make up the organ or tissue (Ribacka, 
C., et al. Ann. Med. epub ahead of print: 1-10 (2008)). 
Many approaches have been employed in the in vitro 
expansion of stem cells in the last decade, and they can be 
45 generally divided into two categories. The first category is 
treatment of stem cells with various combinations of stem cell 
expansion factors. Treatment with combinations of stem cell 
expansion factors has been shown to increase a progenitor/ 
stem cell population by 2- to 30-fold in the relatively short 
50 period of 10 to 14 days. However, it is difficult to maintain 
stem cell activity in long-term cultures even if the total num-
ber of cells could be expanded. The second category involves 
using stromal cells. Several methods of in vitro expansion 
using primary stromal cells have been reported (Gan et al., 
55 Blood 90:641 (1997); Yamaguchi et al., Exp. Hematol. 29:174 
(2001)). When stem cells were co-cultured with primary stro-
mal cells, the stem cells were expanded for 2 to 4 weeks. It is 
hypothesized that stromal cells provide cell-cell or cell-ex-
tracellular matrix cues that may help expand and maintain the 
60 stem cells in an undifferentiated state. However, stem cells 
have frequently lost their pluripotency during in vitro expan-
sion. Maintenance of pluripotency, number, and proliferative 
activity of stem cells is critical for transplantation. In addi-
tion, removal of stromal cells prior to transplantation also 
65 remains a caveat of this category. 
Another type of adult stem cell is the cancer stem cell. It is 
known that a small percentage of cells within an established 
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tumor have the properties of stem cells. These solid tumor 
stem cells give rise to both more tumor stem cells and to the 
majority of cells in the tumor that have lost the capacity for 
extensive proliferation and the ability to give rise to more 
tumors. Thus, solid tumor heterogeneity reflects the presence 
of tumor cell progeny arising from a solid tumor stem cell. 
Presently used means of cancer treatment would thus leave 
the cancer stem cells unharmed and allow them to induce 
regrowth of the tumor after seemingly effective treatment. 
Radiation therapy and most current chemotherapeutic agents 
target replicating cells, with adult stem cells demonstrating 
remarkable resistance to these treatments (Ribacka, C., et al. 
Ann. Med. epub ahead of print: 1-10 (2008)). 
Thus, there is a need to establish stem cell cultures that can 
both expand stem cells and maintain stem cells in their undif-
ferentiated state. In addition, there is a need for methods to 
increase the sensitivity of cancer stem cells to chemotherapy. 
BRIEF SUMMARY OF THE INVENTION 
In accordance with the present invention, it has been found 
that growing stem cells under certain conditions of simulated 
microgravity increases the life span of stem cells along with a 
concomitant increase in telomerase activity and telomere 
length. Additionally, it has been discovered by the present 
inventors that culturing cancer cells under certain conditions 
of microgravity leads to an increase in susceptibility of those 
cancer cells to chemotherapeutic agents. 
One of the many embodiments of the present invention is 
directed to a method for increasing telomere length in stem 
cells comprising obtaining a population of stem cells, seeding 
the stem cells into a hydrodynamic focusing bioreactor 
("HFB"), culturing said stem cells under conditions allowing 
fortelomere growth, isolating said stem cells and determining 
telomere length. 
An aspect of the present invention is directed to a method 
for increasing telomerase activity in stem cells comprising 
obtaining a population of stem cells, seeding the stem cells 
into a HFB, culturing the stem cells under conditions allow-
ing for increased telomerase activity, isolating said stem cells 
and determining telomerase activity. 
Another aspect of the present invention is directed to a 
method for increasing the life span of stem cells comprising 
obtaining a population of stem cells, seeding the stem cells 
into a HFB, culturing said stem cells under conditions allow-
ing for increased life span, isolating the stem cells and deter-
mining telomerase activity, wherein increased telomerase 
activity is indicative of increased life span. 
Another embodiment of the present invention is directed to 
a method for selectively enriching a stem cell population 
comprising obtaining a population of stem cells from the 
peripheral blood, bone marrow, umbilical cord blood and 
amniotic fluid, seeding the stem cells into a HFB, culturing 
the stem cells under conditions allowing for selective enrich-
ment of a stem cell population, and isolating the stem cell 
population. 
Another aspect of the present invention is directed to a 
method for increasing the sensitivity of cancer cells to che-
motherapeutic agents comprising obtaining a population of 
cancer cells, seeding the cancer cells into a HFB, and cultur-
ing the cancer cells under conditions allowing for increased 
sensitivity of the cancer cells to chemotherapeutic agents. 
Another aspect of the present invention is directed to a 
method for growing tissue for use in transplantation compris-
ing growing stem cells in a HFB, allowing the stem cells to 
form into tissue and harvesting the tissue. 
4 
Another aspect of the present invention is directed to a 
method for growing tissue comprising growing cancer stem 
cells in a HFB, allowing the stem cells to form into cancerous 
tissue and harvesting the tissue. 
5 	 Another aspect of the present invention is directed to a 
method for growing tissue for use in transplantation compris-
ing growing cancer stem cells in a HFB, allowing the cancer 
stem cells to form into tissue using a scaffold or guiding 
matrix, killing the cancer cells in the tissue and harvesting the 
io tissue. 
Another aspect of the present invention is directed to a 
method for increasing telomere length in cancer stem cells 
comprising obtaining a population of cancer stem cells, seed-
ing the cancer stem cells into a HFB, culturing the cancer stem 
15 cells under conditions allowing for telomere growth, isolating 
said stem cells and determining the telomere length. 
Another aspect of the present invention is directed to a 
method for increasing telomerase activity in cancer stem cells 
comprising obtaining a population of cancer stem cells, seed- 
20 ing said cancer stem cells into a HFB, culturing the stem cells 
under conditions allowing for increase telomerase activity, 
isolating the stem cells and determining telomerase activity. 
Another aspect of the present invention is directed to a 
method for increasing the life span of cancer stem cells com- 
25 prising obtaining a population of stem cancer cells, seeding 
the stem cells into a HFB, culturing the stem cells under 
conditions allowing for increased life span, isolating the stem 
cells and determining telomerase activity, wherein increased 
telomerase activity is indicative of increased life span. 
so Another aspect of the present invention is directed to a 
method for producing cellular factors comprising obtaining a 
population of stem cells, seeding the stem cells into a HFB, 
culturing the stem cells under conditions allowing for pro-
duction of cellular factors and harvesting said cellular factors. 
35 Another aspect of the present invention is directed to a 
method for producing cellular factors comprising obtaining a 
population of cancer stem cells, seeding the cancer stem cells 
into a HFB, culturing the cancer stem cells under conditions 
allowing for production of cellular factors and harvesting said 
40 cellular factors. 
Another aspect of the present invention is directed to a 
method for testing the effectiveness of chemotherapy drugs 
on cancer stem cells that are normally resistant to chemo-
therapy comprising subjecting the cancer stem cells to micro- 
45 gravity conditions and administering chemotherapeutic 
agents. 
Another aspect of the present invention is directed to a 
method for testing the effectiveness and effects of chemo-
therapy drugs on normal cells comprising subjecting the nor- 
50 mal cells to microgravity conditions and administering a che-
motherapeutic agent. 
Another aspect of the present invention is directed to a 
method for improving the treatment outcome of cancer in a 
mammal comprising subjecting the mammal to microgravity 
55 conditions and administering a chemotherapeutic agent. 
Another aspect of the present invention is directed to a 
method for improving the treatment outcome of cancer that is 
normally resistant to chemotherapy in a mammal comprising 
subjecting the mammal to microgravity conditions and 
6o administering a chemotherapeutic agent. 
Another aspect of the present invention is directed to a 
method for treating, diminishing, reducing the severity of, or 
eradicating cancer in a mammal comprising subjecting the 
mammal to microgravity conditions and administering a che- 
65 motherapeutic agent. 
Another aspect of the present invention is directed to a 
method for treating, diminishing, reducing the severity of, or 
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eradicating cancer that is normally resistant to chemotherapy 	 grown in a Hydrodynamic Focusing Bioreactor (HFB). 
in a mammal comprising subjecting the mammal to micro- 	 CDDP indicates that the cells were treated with cisplatin. 
gravity conditions and administering a chemotherapeutic 	 Omega3 indicates that the cells were treated with omega-3 
agent. 	 fatty acids. 
Another aspect of the present invention is directed to a 5 
method for proliferating cells comprising seeding cancer 	 DETAILED DESCRIPTION OF THE INVENTION 
cells into a Hydrodynamic Focusing Bioreactor and culturing 
said cancer cells in the presence of one or more omega-3 fatty 	 The present invention offers new methods to select and 
acids. 	 proliferate stem cells using a bioreactor to eliminate gravity 
Another aspect of the present invention is directed to a io forces. It has been found that the bioreactor's simulation of 
method for increasing the sensitivity of cancer cells to one or 	 microgravity offers a low shear environment, whichpromotes 
more chemotherapeutic agents comprising seeding cancer 	 co-location of cells. Culture conditions in the bioreactor have 
cells into a Hydrodynamic Focusing Bioreactor and culturing 	 also been found to provide an excellent in vitro system for 
said cancer cells in the presence of one or more omega-3 fatty 	 increasing the telomerase activity of stem cells, thereby unex- 
acids. 	 15 pectedly increasing telomere length and the life span of stem 
cells. Additionally, it has been discovered that the bioreac- 
BRIEF DESCRIPTION OF THE FIGURES 	 tor's microgravity environment is also an exceptional system 
for increasing the susceptibility of cancer cells to chemo- 
The following drawings form part of the present specifica- 	 therapeutic agents to which they would normally be resistant. 
tion and are included to further demonstrate certain aspects of 20 Hydrodynamic Focusing Bioreactor (HFB) 
the present invention. The invention may be better understood 
	
Bioreactors have several advantages over traditional cell 
by reference to one or more of these drawings in combination 	 cultures for the mass cultivation of cells. They provide better 
with the detailed description of specific embodiments pre- 	 control for scale up of cell suspension cultures under defined 
sented herein. 	 parameters for the production of cellular factors. Constant 
FIG.1 shows a HFB with a 40 mL culture chamber. At the 25 regulation of conditions at various stages of bioreactor opera- 
apex of the dome-shaped culture chamber is a sampling port. 	 tion is possible. Handling of culture such as inoculation or 
FIG. 2 shows the number of viable cells recovered after 	 harvest is easy and saves time. Nutrient uptake is enhanced by 
culture of SAOS-2 osteosarcoma cells in HFB for 5 days. 	 submerged culture conditions which stimulate cell multipli- 
FIG. 3 shows the number of viable cells MACSorted with 	 cation rate and promote higher yield of cellular factors. 
an antibody to CD133 and cultured in the HFB for 5 days. 30 	 It is often difficult to attain good oxygen transfer with 
FIG. 4 shows other stem cell markers expressed on 	 conventional bioreactor culture. Suspension of cells is easily 
SAOS-2 osteosarcoma cells, CD133 positive SAOS-2 cells, 	 achievable using stirred technologies. Unfortunately, in 
sorted CD133 positive SAOS-2 cells cultured in the HFB, and 
	
impeller-driven bioreactors stirring invokes deleterious 
unsorted SAOS-2 cells grown in the HFB. 	 forces that disrupt cell aggregation and results in cell death. 
FIG. 5 is a bright field image of cellular cluster formation 35 	 Furthermore, the requirements for media oxygenation cre- 
of sorted CD133 positive SAOS-2 osteosarcoma cells grown 	 ate a foaming in the bioreactor, which also tends to perturb 
in the bioreactor for 3 days (5A, 513, 5C) or in adhering tissue 	 and otherwise damage cells. These factors limit the concen- 
culture dishes for 3 days (51), 5E). 	 tration and density of the bioreactor nutrient culture medium. 
FIG. 6 shows cell clusters formed by SAOS-2 CD133 
	
The conventional bioreactor approach for growing cells has 
positive sorted cells in non-adhering dishes (6A and 613); 40 the disadvantage that the mechanically stirred impellers, 
adherent and differentiated SAOS-2 cells derived from a 	 which damage cells, generate high shear forces and hinder 
SAOS-2 CD133 positive cells grown in adherent culture 	 proper tissue-specific differentiation. 
dishes (6C and 6D); and a SAOS-2 cell line reconstituted after 	 The NASA first generation rotating bioreactors provided 
one week of inoculation of CD133 positive enriched cells in 	 rotation about the horizontal axis which resulted in the sus- 
adhering tissue culture dishes. 	 45 pension of cells without stirring, thus providing a suitable 
FIG. 7 shows flow cytometric analysis of SAOS-2 cells 	 environment to propagate cells without sedimentation to a 
(7A), SAOS-2 cells grown under static growth conditions 	 surface. Unfortunately, these first generation High Aspect 
(713) and SAOS-2 cells grown in the HFB for 5 days (7C) with 	 Rotating Vessel (HARV) bioreactors did not provide a way to 
the use of CD133 (stem cell marker) and Ki-67 (proliferation 	 remove air bubbles that are disruptive to the survival of cells 
marker). 	 5o and the integrity of the tissue-like, three-dimensional cell 
FIG. 8 shows a telomeric repeat amplification protocol 	 constructs. When the HARV bioreactor is used, the cell 
(TRAP) assay comparing Hos osteosarcoma cells grown 	 growth rate is very slow compared to the general shake-flask 
under static growth or in the HFB for 5 or 10 days. 	 culture method, because the lag phase is longer in order to fit 
FIG. 9 shows the results of a chemo -sensitization proce- 	 the circumstance of microgravity. 
dure pertaining to the use of cisplatin. 	 55 	 Conventional bioreactors (including the Clinostat and Syn- 
FIG. 10 shows the results of a chemo -sensitization proce- 	 thecon vessel) rely on agitation to suspend cells and attach- 
dure pertaining to the use of methotrexate. 	 ment materials and to facilitate the mass transfer required for 
FIG. 11 shows the results of a chemo -sensitization proce- 	 the growth of cells and tissue assemblies. However, shear 
dure pertaining to the use of doxorubicin. 	 force generated by agitation can affect cell-cell interactions 
FIG. 12 shows the results of a viability assay of SAOS-2 6o and degrade three-dimensional cellular development. More- 
cells grown in the presence of omega-3 fatty acids. 	 over, air bubbles that form within the culture media in the 
FIG. 13 shows the results of a growth assay of CD133(+) 	 conventional vessels cannot be removed, although such 
SAOS-2 cells grown in the presence or absence of omega-3 	 removal is critical to maintain low shear environment. 
fatty acids. 	 The HFB (see e.g., U.S. Pat. No. 6,001,642, which is 
FIG. 14 shows the results of  viability assay ofCD133(+) 65 hereby incorporated by reference in its entirety) is a horizon- 
SAOS-2 cells grown in the presence or absence of omega-3 	 tally rotating, fluid-filled culture vessel equipped with a mem- 
fatty acids and/or cisplatin. HFB indicates that the cells were 	 brane for diffusion gas exchange to optimize gas/oxygen- 
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supply capable of simulating microgravity. In the HFB, at any 
given time, gravitational vectors are randomized and the 
shear stress exerted by the fluid on the synchronously moving 
particles is minimized. These simulated microgravity condi-
tions facilitate spatial co-location and three-dimensional 
assembly of individual cells into large tissues (Wolf, D. A, 
and Schwartz, R. P., Analysis of gravity-induced particle 
motion and fluid perfusion flow in the NASA-designed rotat-
ing zero-head-space tissue culture vessel, NASA Tech Paper 
3143, Washington D.C. (1991)). 
By the term "microgravity" is meant the near weightless-
ness condition created inside a spacecraft as it orbits the 
Earth. In the simulated microgravity environment of the HFB 
where there is no buoyancy, no convection, no stratification of 
layers, and where surface tension dominates, major impacts 
on metabolism will be reflected in the biosynthetic potential 
of cultured cells andprotoplasts. This is in contrastto "normal 
gravity" or "static conditions" by which is meant, the normal 
or usual gravitational force exerted on earth in a gravity- 
unmanipulated environment, also represented as "1G" or 
« 1 _g» 
There are also significant advantages of such a system over 
a 1-g microenvironment found in shaker flasks. For example, 
cell cultures can be grown and maintained under controlled 
conditions with respect to nutritional and environmental 
requirements. Such a situation would allow establishment of 
conditions for optimal cell growth. 
Cell culture conditions in the simulated microgravity envi-
ronment of the HFB combine two beneficial factors: low 
shear stress, which promotes the assembly of tissue-like, 
three-dimensional cell constructs; and randomized gravita-
tional vectors. Close apposition of the cells in the absence of 
shear forces promotes cell-cell contacts, and cell aggregation. 
This process then leads to the rapid establishment and expan-
sion of tissue-like cultures, which unlike cells cultured in 
conventional bioreactors, are not disrupted by shear forces. 
This microgravity environment of the HFB keeps cells 
suspended in the fluid medium without imparting shear forces 
that are common in conventional bioreactors. Before the 
introduction of the HFB, the on-orbit formation of air bubbles 
in culture fluid and attempts at removing these bubbles from 
the fluid medium of the HighAspect Rotating Vessel (HARV) 
bioreactor degraded both the low-shear cell culture environ-
ment and the delicate three-dimensional tissues. Unlike the 
HARV bioreactor, the HFB employs a variable hydrofocus-
ing force that can control the movement, location and removal 
of suspended cells, three-dimensional tissues, and air bubbles 
from the bioreactor. Only gentle mixing is required to distrib-
ute nutrients and oxygen. These factors allow higher concen-
trations and densities to be achieved in a low g environment. 
Additionally, since the cells do not need to maintain the same 
surface forces that they require in Earth-normal gravity, they 
can divert more energy sources for growth, the biosynthesis 
of more products, or even novel products. This allows the 
ability to impose variable gravity on these cell systems and 
the means to test the consequences of increasing or decreas-
ing g forces on cellular factors. 
The HFB is a cell culture apparatus that employs hydrody-
namic focusing to simulate microgravity. The HFB contains a 
rotating, cell culture chamber and an internal viscous spinner. 
The chamber and spinner can rotate at different speeds in 
either the same or opposite directions. Rotation of the cham-
ber and viscous interaction at the spinner generate a hydro-
focusing force. Adjusting the differential rotation rate 
between the chamber and spinner controls the magnitude of 
the hydrofocusing force and the co-location of contents 
within the culture chamber 
8 
By the term "bioreactor" is meant an apparatus, such as a 
large chamber, for growing organisms such as bacteria, yeast, 
plant or mammalian cells that are used in the biotechnological 
production of substances such as pharmaceuticals, biophar- 
5 maceuticals, antibodies, vaccines, or for the bioconversion of 
organic waste. 
By the term "hydrodynamic focusing bioreactor" is meant 
a bioreactor that relies on the principle of hydrodynamic 
focusing to control the movement of contents within the 
io culture chamber of the bioreactor. By the term "hydrody-
namic focusing" is meant relating to, or operated by the force 
of liquid in motion to control the movement of contents 
within the culture chamber of the bioreactor. The HFB offers 
a unique hydrofocusing capability that enables the creation of 
15 a low-shear culture environment simultaneously with the 
"herding" of suspended cells, tissue assemblies, and air 
bubbles. 
By the term "culture chamber" is meant the enclosed space 
or compartment in which stem cells are cultured. In one 
20 embodiment of the present invention, the HFB is a horizon-
tally-rotating bioreactor. In another embodiment, the biore-
actor has both a culture chamber and an internal viscous 
spinner. The culture chamber and the internal viscous spinner 
can be horizontally rotated to produce a hydrofocusing force 
25 on the contents of the culture chamber. The culture chamber 
can also be rotated in the same direction and at the same speed 
as the internal viscous spinner. The culture chamber can be 
horizontally-rotated at a rate from about 1 RPM to about 30 
RPM in 1 RPM increments. The internal viscous spinner can 
3o be horizontally-rotated from about 1 RPM to about 99 RPM, 
in 1 RPM increments. In a preferred embodiment, the cham-
ber and the spinner are rotated at 25 rpm. 
By the term "differential rate" is meant the difference 
between the rotational rate of the culture chamber and the 
35 rotational rate of the innerviscous spinner. The bioreactor can 
have a differential rate from about 0 RPM to about 129 RPM. 
Preferably, the bioreactor differential rate is from 0 to 110 
RPM. More preferably, the bioreactor differential rate is 
between 0 and 75 RPM. In one embodiment, the chamber and 
40 the spinner are rotated in the same direction at the same speed 
corresponding to a differential rate of zero. This allows cells 
to be concentrated in front of the spinner, which has the shape 
of a cone. 
The culture chamber can also be rotated in the opposite 
45 direction as the internal viscous spinner. The rate of rotation 
for the culture chamber may be higher than the rate of rotation 
of the internal viscous spinner, lower than the rate of rotation 
of the internal viscous spinner or the same as the rate of 
rotation of the internal viscous spinner. The bioreactor may 
5o also have a dome-shaped culture chamber. 
The HFB culture chamber has a volume between about 10 
mL and about 10 L. (See e.g., PCT publication WO 
00/00586.) Small and medium scale laboratory cultures can 
be performed in culture chambers of 100 mL, 160 mL, 250 
55 mL, and 500 mL volumes. In one embodiment, the bioreactor 
has a culture chamber volume of about 40 mL. Larger pre-
parative scale cultures can be performed in culture chambers 
of 1 L, 5 L, and 10 L volumes. In another embodiment, the 
bioreactor has a culture chamber volume of 1, 2, 3, 4, 5, 6, 7, 
60 8, 9 or 10 L. The bioreactor culture chamber can have perfu-
sion ports to allow for gas exchange. The bioreactor culture 
chamber can have a sample port that allows for extraction of 
media, cells or air. 
In one embodiment, the bioreactor allows co-location of 
65 cells with similar or differing sedimentation properties in a 
similar spatial region within the culture chamber. In another 
embodiment, the bioreactor allows freedom for the three- 
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dimensional spatial orientation of stem cell or somatic cell 
	
WA09, WA13, WA14. The stem cells according to the present 
tissues formed by the culturing of the stem cells. In yet 	 inventionmay also be modified stem cells. The modified stem 
another embodiment, low shear and essentially no relative 	 cells may be genetically modified to increase production of a 
motion of said culturing environment is observed with respect 	 cellular factor(s) including growth factors, cytokines, differ- 
to the walls of the culture chamber. The resulting force within 5 entiation factors, and hormones. 
the bioreactor suspends cells in a low-shear environment such 
	
A stem cell population of the present invention may also be 
that a maximum force of about 0.01 dyne/cm 2 is experienced 	 selectively enriched by obtaining a population of stem cells, 
by the cell, more preferably the maximum force is about 	 seeding the stem cells into a HFB, culturing the stem cells 
0.001 dyne/cm2. Another aspect of the invention is to a 	 under conditions allowing for selective enrichment of a stem 
method for culturing stem cells in a HFB, whereby the result-  io cell population, and isolating the stem cell population. Pre- 
ing force within the bioreactor suspends cells in a low-shear 	 ferred conditions include loading the bioreactor with an 
environment such that a maximum force of about 0.5 dyne/ 	 enriched stem cell population preselected by MACSorting or 
cm2 is experienced by the stem cells. 	 loading a heterogenous population from which the stem cells 
Stem Cells 	 can be selected by the microgravity environment. A popula- 
There are several different types of stem cells, including 15 tion of stem cells is selectively enriched by the following 
embryonic stem cells, adult stem cells, and cancer stem cells. 	 procedure: the microgravity environment of the bioreactor 
By the term "stem cells" is meant undifferentiated cells that 	 provides a mechanism for selecting stem cells by apoptosis of 
are characterized by the ability to renew themselves through 	 the differentiated cells present in the heterogenous popula- 
mitotic cell division and differentiation into a diverse range of 	 tion. 
specialized cell types. 	 20 Telomeres and Telomerase 
Furthermore, stem cells according to the current invention 	 The present inventors have discovered that stem cells 
may be embryonic stem cells, adult stem cells, umbilical cord 	 grown under conditions of simulated microgravity show 
blood stem cells, somatic stem cells or cancer stem cells. 	 enhanced telomerase activity and thus an increase in telomere 
Additionally, the stem cells of the current invention may be 	 length. The telomere is a functional complex consisting of 
hematopoietic stem cells, or mesenchymal stem cells. The 25 tandem guanine rich repeated DNA and its associated pro- 
stem cells of the current invention may be totipotent, pluri- 	 teins located at the ends of each linear chromosome (Cong, U. 
potent, multipotent or unipotent stem cells. Stem cells 	 and Shay, J. W., Cell Res. 18:725-732 (2008)). In human 
according to the current invention may be selected for by the 	 chromosomes, telomeres consist of thousands of copies of 6 
presence of one or more stem cell markers including but not 	 base repeats (TTAGGG). The function of the telomere is to 
limited to: CD133, CD34, CD38, CD117/c-kit, OCT3/4, 30 protect chromosomes from end to end fusions, recombina- 
Nanog, RUNX2, SOX9, Integrin, SPARC, osteocalcin, 	 tion, and terminal DNA degradation. The length of the short 
endoglin and STRO-1. In one embodiment, the stem cells 	 guanine-rich repeat sequences is heterogeneous among indi- 
express CD133. In another embodiment, the stem cells 	 viduals ranging between 5 and 20 Kb according to age, organ 
express CD34. In yet another embodiment, the stem cells 	 and the proliferate history of each cell (Hiyama E. and 
express Ki-67. 	 35 Hiyama, K., British J. Cancer 96:1020-1024 (2007)). During 
The stem cells of the current invention may be primary 	 DNA synthesis and cell division, telomeres shorten as a result 
stem cells or may be derived from an established stem cell 	 of incomplete replication of linear chromosomes. This pro- 
line, premalignant stem cell line, cancer cell line, or any cell 	 gressive telomere shortening is one of the molecular mecha- 
line that manifests any stem cell marker. Primary stem cells 	 nisms underlying ageing, as critically short telomeres trigger 
may be derived from a cancer patient or a healthy patient. 	 40 chromosome senescence and loss of cell viability. Id. 
According to the present invention, primary stem cells can 	 Telomeres can be lengthened, however, by a complex of a 
be derived from a cancer patient who has any type of cancer 	 reverse transcriptase protein encoded by the TERT gene and 
including but not limited to a liquid tumor and a solid tumor. 	 a template RNA TERC, which together form the enzyme 
By the term "liquid tumor" we mean any tumor, cancer or 	 telomerase. Telomerase can add telomeric repeats onto the 
malignancy that occurs in the fluid of a patient's body, for 45 chromosome ends and prevent the replication dependent loss 
instance blood or lymph. By "solid organ tumor" we mean 	 of telomere and cellular senescence. Therefore, telomerase 
any tumor that occurs in a solid organ of a patient's body or 	 activity and telomere length maintenance are associated with 
put another way, any tumor that occurs anywhere but in the 	 the immortality of cancer cells, germ line cells and embryonic 
liquid of a patient's body. In particularly preferred embodi- 	 stem cells. 
ments the cancer is selected from the group consisting of 50 	 Thus, an aspect of the present invention is directed to a 
leukemia, lymphoma, lung cancer, breast cancer, prostate 	 method for increasing the length of telomeres in stem cells by 
cancer, brain cancer, pancreatic cancer, liver cancer, skin 	 obtaining a population of stem cells, seeding said stem cells 
cancer and bone cancer. 	 into a HFB, culturing said stem cells under conditions allow- 
Suitable cancer stem cell lines according to the current 	 ing for telomere growth and determining the telomere length. 
invention include but are not limited to: SAOS-2, Hos, U20S 55 By "conditions allowing for telomere growth" is meant any 
(human osteosarcoma), T98G and U87MG (human glioblas- 	 culture condition which leads to an increase in telomere 
toma), Du145 and LNCap (human prostate adenosarcoma), 	 growth in the stem cell. A preferred culture condition is grow- 
WI38 and H23 (human lung fibroblast and lung adenosar- 	 ing the cells in microgravity environment for 1 to 15 days as 
coma, respectively), Hep3b (human hepatocarcinoma), and 	 in Example 8. Telomere length can be indirectly measured by 
HeLa (human cervical cancer), Mewo and HO-1 cells (human 60 methods known in the art such as the telomeric repeat ampli- 
melanoma), HN12 and HN30 cells (human Head and Neck 	 fication protocol (TRAP) assay. The quantification of telom- 
SquamoCellular Carcinoma). 	 erase activity can be measured by TRAP assay. The methods 
Suitable stem cell lines according to the current invention 	 of the current invention lead to an increase in telomere length 
include but are not limited to the following cell lines (NIH 	 of 6 to 24 repeats when compared to stem cell cultures grown 
Code): BGOI, BG02, BG04, SA01, SA02, SA03, ESOI, 65 under static conditions. 
ES02, ES03, ES04, ES05, ES06, TE03, TE32, TE33, TE04, 	 Another aspect of the present invention is directed to a 
TE06, TE62, TE07, TE72, UCOI, UC06, WA01, WA07, 	 method for increasing telomerase activity in stem cells by 
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obtaining a population of stem cells, seeding said stem cells 	 embodiment, the upperpH limit for medium exchange will be 
into a HFB, culturing said stem cells under conditions allow- 	 about pH 7.4. One of skill in the art will recognize that the pH 
ing for an increase in telomerase activity and assaying for 	 value for optimal cell growth, protein, metabolite or chemical 
telomerase activity. By "conditions allowing for an increase 	 production will vary with the culture conditions, the type of 
in telomerase activity" is meant any culture condition which 5 cells, and the cellular factor being produced. Measurement of 
leads to an increase in telomerase activity in the stem cell. A 	 pH is well known to those of skill in the art. The pH can be 
preferred culture condition is exposing the cells to the micro- 	 measured using a pH electrode in combination with a device 
gravity environment from 1 to 15 days, including, but not 	 for reporting the pH. The pH can also be detected using pH 
limited to the combination of either commonly used media 	 sensitive dyes, usually bound to a paper support. The pH 
for cell culture such as RPMI-1640, E-MEM, D-MEM, in the io electrodes, pH meters, and pH paper are all commercially 
presence or absence of fetal bovine serum (FBS), calf serum 	 available from, for example, Fisher Scientific, Inc., and Broa- 
(CS), or specially designed media for stem cell culture includ- 	 dley-James Corporation. The bioreactor will preferably 
ing growth factors. An increase in telomerase activity can be 	 include means to measure pH levels in the culture media. 
measured by methods known in the art such as TRAP assay, 	 Change in pH can be monitored, not measured, by presence in 
TRAP enzyme linked immuno-sorbant assay (TRAP 15 the medium of pH sensitive dyes such as phenol-red. The 
ELISA), transcription mediated amplification (TMA), and 	 media containing the pH sensitive dye are commercially 
analysis of the hTERT transcript. The methods of the current 	 available from, for example, Fisher Scientific, Inc. and Cell- 
invention lead to a 1 to 5 fold increase in telomease activity 	 Grow. 
when compared to stem cells grown in static conditions. 	 Cells are grown under sterile conditions with controlled 
Another aspect of the present invention is directed to a 20 dissolved 02 levels. One of skill in the art would know how to 
method of increasing the life span in stem cells by obtaining 	 measure dissolved oxygen levels in media, and how to use 
a population of stem cells, seeding said stem cells into an 	 those levels to determine the rate of oxygen consumption over 
HFB, culturing said stem cells under conditions allowing for 	 time. Dissolved oxygen sensors are commercially available 
an increase in life span and assaying for increased telomerase 	 from, for example, Broadley-James Corporation and Mettler 
activity, wherein an increase in telomerase activity is indica-  25 Toledo Corporation. In one embodiment, the method includes 
tive of increased life span. By "conditions allowing for an 	 adjusting the dissolved oxygen levels of the culture medium. 
increase in life span," is meant any culture condition which 
	
In a particular embodiment, the dissolved oxygen levels in the 
leads to an increase in life span of the stem cell. A preferred 	 culture medium can be elevated by using a bubble-trap oxy- 
culture condition is exposing the cells to the microgravity 	 genator. In another embodiment, the method includes adjust- 
environment from 1 to 15 days, including but not limited to 30 ing the oxygen levels of the culture incubator in which the 
the combination of either commonly used media for cell 
	
bioreactor culture chamber is rotating. The bioreactor will 
culture such as RPMI-1640, E-MEM, D-MEM, in the pres- 	 preferably include means to measure dissolved 0 2 levels. 
ence or absence of FBS or CS, or specially designed media for 	 Measurements can be taken online, within the bioreactor 
stem cell culture including growth factors. 	 culture chamber or measurements can be taken offline, after 
Growth Conditions 	 35 samples of the medium have been withdrawn from the culture 
Growth conditions according to the present invention are 	 chamber, however, online measurements are preferred. These 
any conditions that allow for growth of the cultured stem 	 operations are included with HFB bioreactors commercially 
cells. It is contemplated that the media within the culture 	 available from, for example, Celdyne Corp. 
chamber of the bioreactor can be oxygenated. It is also con-  The stem cells of the current invention are preferably cul-
templated that the byproducts formed within the culture 40 tured at a temperature of about 35° to about 39° C., more 
chamber of the bioreactor can be removed. These byproducts preferably at a temperature of about 37° C. 
can be removed through the sampling port of the HFB. By the 	 Additionally, the stem cells of the current invention are 
term "byproducts" is meant substances left over from stem 	 preferably cultured in the HFB for about 1 to about 35 days, 
cell culture. In one embodiment, air bubbles formed within 	 about 1 to about 25 days, about 1 to about 15 days, about 3 to 
the culture chamber of the bioreactor can be removed. Air 45 about 7 days, or for about 3, 5 or 7 days. 
bubbles can be removed through the sampling port of the 	 The stem cells of the current invention are cultured at an 
HFB. 	 initial concentration of about 0.5 to about 2.5 x10 3 cells/mL of 
Media is exchanged from the bioreactor vessel for a variety 	 medium, or even up to 5x10 4 cells/mL of medium or up to 
of reasons, including to induce protein, lipid, nucleic acid, 	 1 x10 6 cells/mL of medium, more preferably at a concentra- 
metabolite or chemical production, byproducts, or to restart 50 tion of about 2.5x105 cells/mL medium or 0.5x10 6 cells/mL 
growth of the cells after nutrient depletion. One of skill in the 	 medium. 
art will understand that media exchange can be carried out in 	 In addition, the rotational speed of the HFB in accordance 
a variety of ways. Sterile media can be added after filtration 	 with the present invention is from about 1 to about 30 rpm, 
through a sterile filter. Fresh medium can be added to the 	 more preferably about 25 rpm. 
cells. The fresh medium may have the same components or 55 	 Additionally, the stem cells according to the current inven- 
different components than the original unspent medium. For 	 tion are cultured in a culture medium comprising from about 
example, "induction medium" may be exchanged with 
	
0 to about 20 percent serum, preferably from about 0 to about 
"growth medium," or the reverse may also occur. By the term 	 10 percent, most preferably 10 percent. The serum can be 
"induction medium" is meant culture medium which pro- 	 from any usual source for use in cell culture. In a preferred 
vides a culture environment that activates transcription or 60 embodiment, the serum is fetal bovine serum. 
alleviates repression of transcription from an inducible pro- 	 In addition, the culture medium may also contain antibiot- 
moter. By the term "inducing agent' is meant byproducts 	 ics and/or antifungals. Any antibiotic or antifungal for use in 
present in conditioned media that allow for the enhanced 	 cell culture may be used, such as penicillin, streptomycin, 
production of a cellular factor of interest. 	 gentamycin, hygromycin, kanamycin, neomycin, puromycin 
When cells proliferate, the pH of the medium lowers as 65 and tetracycline. The antibiotics can be present in amounts 
catabolites are released in the medium. The methods further 	 that are non-toxic to the cell culture of between 1 unit/mL and 
include adjusting the pH of the fluid culture medium. In one 	 100 units/mL, or between 1 µg/mL and 100 µg/mL. 
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The culture medium may also contain amino acids or mix-
tures of essential and/or non-essential amino acids. The 
amino acids can be present in an amount of between 1 unit/ 
mL and 100 units/mL, or between 1 µg/mL and 100 µg/mL. 
The medium may also contain stem cell growth factors. 5 
Examples of stem cell growth factors suitable in accordance 
with the present invention include but are not limited to: 
Flk-2/Flt-3 ligand (FL), stem cell factor (SCF), thrombopoi-
etin (TPO), granulocyte-colony stimulating factor (G-CSF), 
megakaryocyte growth and development factor (MGDF), l0 
interleukin-3 (IL-3), and IL-6. 
The culture medium may also contain one or more 
omega-3 fatty acids. Omega-3 fatty acids that can be used in 
various aspects of the present invention include a-linolenic 15 
acid, eicosapentaenoic acid (EPA), docosapexaenoic acid 
(DHA), stearidonic acid (STD), eicosatrienoic acid (ETE), 
eicosatetraenoic acid, docosapentaenoic acid (DPA), tetra-
cosapentaenoic acid, tetracosahexaenoic acid (nisinic acid), 
and combinations thereof. The use of other omega-3 fatty 20 
acids known in the art is also contemplated. The omega-3 
fatty acids can be used in concentrations between about 0.1 
µM and about 100 µM. More preferably, they can be used in 
concentrations of between about 1 nM and about 100 µM, 
between about 1 µM and 100 µM, between about 10 µM and 25 
about 100 µM, between about 20 µM and about 80 µM, 
between about 30 µM and about 70 µM and between about 50 
µM and about 60 µM. Most preferably, they are used in 
concentrations of about 25 µM, about 50 µM or about 75 µM. 
Chemotherapeutic Agents 30 
Chemotherapy, or the use of chemotherapeutic agents, to 
destroy cancer cells is a mainstay in the treatment of malig-
nancies. By the term "chemotherapeutic agents" is meant any 
pharmacological agent that is of use in the treatment of can-
cer. Most chemotherapeutic agents kill cancer cells by affect - 35 
ing DNA synthesis. Examples of classes of chemotherapeutic 
agents include alkylating agents, inhibitors of topoisomerase 
II, cytoskeletal disrupters, nucleoside analogs, platinum 
based agents, retinoids, anthracyclines, nitrosoureas, antime-
tabolites, antitumor antibiotics, vinca alkaloids, and steroid 40 
hormones. Specifically, chemotherapeutic agents of the cur-
rent invention include one or more of cyclophosphamide, 
mechlorethamine, chlorambucil, melphalan, daunorubicin, 
doxorubicin, epirubicin, idarubicin, mitoxantrone, valrubi-
cin, paclitaxel, docetaxel, etoposide, teniposide, tafluposide, 45 
azacitidine, azathrioprine, cytarabien, doxifluridine, fluour-
ouracil, gemcitabine, meracaptopurine, methotrexate, 
tioguanine, bleomycin, carboplatin, cisplatin, oxaliplatin, all-
trans retinoic acid, vinblastine, vincristine, vindesine, and 
vinorelbine. Most preferably, chemotherapeutic agents of the 50 
current invention include cisplatin, doxorubicin and methotr-
exate. 
Chemotherapeutic amounts for in vivo chemotherapy are 
well known. For example, amounts that can be added to cell 
cultures are from about 1 to about 20 µg/mL of cisplatin, from 55 
about 5 to about 15 µg/mL, about 5, about 10, or about 15 
µg/mL cisplatin; about 1 to about 50 µg/mL of methotrexate, 
from about 4 to about 45 µg/mL, most preferably about 4, 11, 
22, or about 45 µg/mL methotrexate; or from about 0.25 to 
about 5 µg/mL of doxorubicin, from about 0.5 to about 2.5 60 
µg/mL, or about 0.5,1.1, or about 2.5 µg/mL doxorubicin may 
be used in accordance with the invention. 
Chemotherapeutic agents may be administered to a mam-
mal, such as a human patient, in need thereof by any means of 
administration including oral, intravenous, subcutaneous, 65 
transdermal, transmucosal, intramuscularly or intraperito-
neally. One of ordinary skill in the art would recognize in 
what manner and at what dose a specific type of chemothera-
peutic agent in a specific mammal should be used. 
Cellular Factors 
Many types of cellular factors can be mass-produced using 
the present invention. By the term "cellular factor" is meant a 
substance that is produced by a cell. The cellular factors being 
produced include: proteins, lipids, nucleic acids, metabolites, 
biochemicals, and byproducts. Some of the proteins of inter-
est include without limitation, growth factors, differentiation 
factors, cytokines, therapeutic proteins, antibodies, enzymes, 
protease inhibitors, transport proteins, storage proteins, pro-
tein toxins, hormones, and structural proteins. Since cells are 
retained in the chamber culture during continuous culture, the 
cellular factor is preferably secreted into the medium. Cellu-
lar factors may be native to the stem cell or encoded by genes 
"endogenous" to the stem cell. For example, stem cells of the 
bone will express bone morphogenic proteins (BMPs). Other 
examples of cellular factors include, transcription factors, 
kineases, kinase inhibitors, cyclins, tumor suppressor genes, 
oncogenes, transmembrane proteins, receptors, secreted pro-
teins, enzymes, protoenzymes, diffusible proteins, secreted 
proteins, antiangiogenic proteins, proangiogenic proteins, 
intracellular proteins, cytoplasmic proteins, nuclear proteins, 
RNA trafficking proteins, DNA trafficking proteins, ion traf-
ficking proteins, chaperones, ubiquitones, sumolating pro-
teins, differentiating proteins, chondrogenic proteins, inter-
leukins, and any other factors or cellular products synthesized 
by a mammalian cell. 
Alternatively, cellular factors may be expressed from trans-
genic stem cells. Transgenic stem cells may carry an "exog-
enous" gene that encodes a protein of interest. Proteins 
expressed from exogenous genes may be engineered to 
include a signal peptide for secretion, if the protein is not 
normally secreted. 
The presence of cellular factors made by stem cells can be 
assayed. Stem cells that are secreted into the media can be 
collected with media through the sampling port. Cellular 
factors that are retained in stem cells can be collected in cell 
culture samples through the sampling port. In one embodi-
ment of the present invention, the cellular factors being 
assayed are selected from the group consisting of: proteins, 
lipids, nucleic acids, metabolites, biochemicals, and byprod-
ucts. Cellular factors in stem cells obtained with media, as 
well as cellular factors obtained by harvesting cell culture 
samples, can be purified and concentrated by methods known 
to those of skill in the art. In one embodiment, the presence of 
cellular factors can be determined by purifying the cellular 
factors from cell lysates or other complex mixtures through 
reverse-phase HPLC, capillary electrophoresis, ion 
exchange, or size exclusion chromatography. 
In another embodiment, the cellular factor is a protein. In 
one embodiment, the protein can be assayed by its level of 
expression. In another embodiment, the protein can be 
assayed by determining its catalytic activity. In another 
embodiment, the protein can be assayed by determining its 
ability to bind to other proteins and small molecules by mea-
suring its dissociation constant (K,). By the term "dissocia-
tion constant' is meant the equilibrium constant for a revers-
ible dissociation reaction. By the term "equilibrium constant' 
is meant the ratio of concentrations of reactants and products 
when equilibrium is reached in a reversible reaction. By the 
term "equilibrium" is meant the state at which rate of the 
forward chemical reaction equals the rate of the reverse 
chemical reaction. 
When the cellular factor is a protein from a transgenec stem 
cell, DNA transgenes may be introduced into the genome of 
the stem cell host by a variety of conventional techniques. For 
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example, the DNA constructs may be introduced directly into 
the genomic DNA of the stem cell using techniques such as 
electroporation and microinjection of stem cell cytoplasm, or 
the DNA constructs can be introduced directly to stem cells 
using ballistic methods, such as DNA particle bombardment. 
Other ways of introducing transgenes is with the use of viral 
particles such as retroviruses or adenoviruses that will trans-
fer the RNA or DNA construct into the target cell. 
If an appropriate antibody is available, immunoassays can 
be used to qualitatively or quantitatively analyze the cellular 
factor produced by the present invention. A general overview 
of the applicable technology can be found in Harlow & Lane, 
Antibodies: A Laboratory Manual (1988). 
The proteins of interest can be detected and/or quantified 
using any of a number of well-recognized immunological 
binding assays (see, e.g., U.S. Pat. Nos. 4,366,241; 4,376, 
110; 4,517,288; and 4,837,168). For a review of general 
immunoassays, see also Methods in Cell Biology: Antibodies 
in Cell Biology, volume 37 (Asai, ed. 1993); Basic and Clini-
cal immunology (Stites & Terr, eds., 7th ed. 1991). Immuno-
logical binding assays (or immunoassays) typically use an 
antibody that specifically binds to an antigen of choice. The 
antibody may be produced by any of a number of means well 
known to those of skill in the art and as described in Harlow 
& Lane, Antibodies: A Laboratory Manual (1988). 
Western blot (immunoblot) analysis may be used to detect 
and quantify the presence of a protein of interest in the 
sample. Western blot analysis can further be used to ensure a 
full-length protein has been produced. The technique gener-
ally comprises separating sample proteins by gel electro-
phoresis on the basis of molecular weight, transferring the 
separated proteins to a suitable solid support, (such as a 
nitrocellulose filter, a nylon filter, or derived nylon filter), and 
incubating the sample with the antibodies that specifically 
bind the protein of interest. The antibodies may be directly 
labeled or alternatively may be subsequently detected using 
labeled secondary antibodies (e.g., labeled sheep anti-mouse 
antibodies) that specifically bind to the primary antibodies. 
Many different cellular factors can be expressed using the 
present invention; thus, many different assays for functional 
compounds may be employed. One of skill in the art will be 
aware of the particular assay most appropriate to determine 
the functional activity of the expressed cellular factors. 
Therapeutic Uses 
The inventors have discovered that culturing stem cells 
under microgravity conditions is useful for several applica-
tions. For example, stem cells grown under microgravity 
conditions form three-dimensional tissues for transplanta-
tion. Examples of tissues that can be grown for transplant 
include, bone, teeth, skin, cartilage, an internal organ, tissue 
derived from hair follicles, liver, pancreas, cornea, kidney, 
heart, muscle or brain. Additionally, cancer stem cells grown 
under microgravity conditions display increased sensitivity 
to chemotherapeutic agents, which is useful in the treatment 
of cancer. In addition, a mammal with cancer can be subjected 
to simulated microgravity conditions in accordance with the 
present invention to increase the sensitivity of the cancer stem 
cells of the mammal to chemotherapeutic agents, thereby 
improving the treatment outcome of cancer in the mammal. 
All references cited in the Examples are incorporated 
herein by reference in their entireties. 
EXAMPLES 
Example 1 
Operation of the HFB 
The HFB is an enabling technology for three-dimensional 
cell culture and tis sue engineering investigations both in labo- 
16 
ratories on Earth and on orbiting spacecraft. The HFB used in 
establishing SAOS-2 cell suspension cultures contains a 
rotating, dome-shaped cell culture chamber with a centrally 
located sampling port and an internal viscous spinner (see 
5 FIG. 1). The chamber and spinner can rotate at different 
speeds in either the same or opposite directions. Rotation of 
the chamber and viscous interaction at the spinner generate a 
hydrofocusing force. Adjusting the differential rotation rate 
between the chamber and spinner controls the magnitude of 
10 the force. The HFB is equipped with a membrane for diffu-
sion gas exchange to optimize gas/oxygen supply. Under the 
microgravity conditions of the HFB, at any given time, gravi-
tational vectors are randomized and the shear stress exerted 
by the fluid on the synchronously moving particles is mini- 
15 mized. These simulated microgravity conditions facilitate 
spatial co-location and three-dimensional assembly of indi-
vidual cells into large tissues (See e.g., Wolf, D. A. and 
Schwartz, R. P., Analysis of gravity-induced particle motion 
and fluid perfusion flow in the NASA-designed rotating zero- 
20 head-space tissue culture vessel., Washington D.C., NASA 
Tech Paper 3134, (1991).) In promoting three-dimensional 
tissue culture, an average shear value of 0.001 dynes/cm 2 was 
estimated for a rotation rate of 10 RPM. (See, e.g., Gonda, S. 
R. and Spaulding, G. F., Hydrofocusing Bioreactor for Three- 
25 Dimensional Cell Culture, NASA Tech Brief MSC-22538, 
Washington D.C. (2003).) 
The HFB model used to establish SAOS-2 cell suspension 
cultures is the HFB-40 mL, Celdyne, Inc., Houston, Tex. This 
model is supplied with a 40 mL culture chamber and a dif- 
30 ferential spinner drive to facilitate the positional control of 
cells and tissues within the chamber. The chamber rotation 
rate can be set with crystal-controlled accuracy from 1 to 30 
RPM in 1 RPM increments. The HFB is operated inside of a 
Laminar Flow Hood. Aspetic techniques are employed when 
35 adding culture medium or innoculum to the culture chamber. 
After culture medium or innoculum medium addition, air 
bubbles are extracted via the sampling port to ensure that the 
HFB culture chamber is air-tight. 
40 	 Example 2 
Selection of Cancer Cells in the HFB 
SAOS-2 osteosarcoma cells were seeded into a HFB at 
45 concentrations ranging between about 2.5x10 3 cells/mL to 
5 x104 cells/mL medium. Therotational speed of the HFB was 
25 rpm and the microgravitational force exerted by the HFB 
was 0.0174 g. The cells were grown in an incubator under 
these conditions: D-MEM medium containing 10% FBS, 1 
50 mM L-Glutamine, 100 U/mL Penicillin, and 100 µg/mL of 
Streptomycin was used at 37° C. and with 5% CO z for 5 days. 
After 5 days, the cells were assayed for viability by trypan 
blue exclusion cell count. The results show that compared to 
control cells, SAOS-2 cells grown in the HFB showed sig- 
55 nificantly lower viability (see FIG. 2) 
Example 3 
Sorted CD133' Stem Cells Derived from SAOS-2 
60 	 Cells Proliferate in HFB 
SAOS-2 cells were MACSorted with an antibody against 
CD133 conjugated to magnetic beads. The sorted CD133 
positive cells were grown in the HFB as in Example 2. After 
65 5 days, cells were assayed for viability by trypan blue exclu- 
sion cell count. In three separate experiments, after 5 days, 
sorted CD133' cells had expanded significantly, by approxi- 
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mately 2-3 fold (see FIG. 3). CD133 positive MACSorted 
SAOS-2 osteosarcoma cells were seeded into a HFB at a 
concentration of about 2x10 4 cells/mL medium. The rota-
tional speed of the HFB was 25 rpm and the microgravita-
tional force exerted by the HFB was 0.0174 g. The cells were 
grown in an incubator under these conditions: D-MEM 
medium containing 10% FBS, 1 mM L-Glutamine, 100 
U/mL penicillin, and 100 µg/mL of Streptomycin was used at 
37° C. and with 5% CO z for 5 days. After 5 days, the cells 
were assayed for viability by trypan blue exclusion cell count. 
Example 4 
Optimization of Proliferation in HFB of Sorted 
CD133' Stem Cells Derived from SAOS-2 Cells 
SAOS-2 cells were MACSorted with an antibody against 
CD133 conjugated to magnetic beads. The sorted CD133 
positive cells were grown in the HFB as in Example 2. After 
7 days, cells were assayed for viability by trypan blue exclu-
sion cell count. In three separate experiments, after 7 days, 
sorted CD133' cells had expanded significantly, by approxi-
mately 15 fold (see FIG. 4). CD133 positive MACSorted 
SAOS-2 osteosarcoma cells were seeded into a HFB at a 
concentration of about 5x10 2 cells/mL medium. The rota-
tional speed of the HFB was 25 rpm and the microgravita-
tional form exerted by the HFB was 0.0174 g. The cells were 
grown in an incubator under these conditions: D-MEM con-
taining 10% FBS, 1 mM L-Glutamine, 100 U/mL penicillin, 
and 100 µg/mL of streptomycin was used at 37° C. and with 
5% COz for 7 days. We achieved a 15-fold proliferation of 
CD133' cancer stem-like cells from the parental SAOS-2 
cells over a seven-day period by stopping the reactor every 24 
hours and gently mixing the culture 10 times in an orthogonal 
manner over a period of one minute, which allowed for redis-
tribution of the media in the dome and mixing of the nutrient 
with the proliferating cells. 
Example 5 
SAOS-2 Cells Cultured in the HFB Display 
Increased Expression of Stem Cell Markers 
To further characterize these cells, sorted CD133' SAOS-2 
cells grown for 5 days in static culture, sorted CD133' 
SAOS-2 cells grown for 5 days in the HFB, unsorted SAOS-2 
cells grown in static culture, and unsorted SAOS-2 cells 
grown in HFB were assayed for the presence of other stem 
cell markers (RUNX2, SOX9, Integrin, SPARC, osteocalcin, 
Endoglin, and STRO-1). The results show that for all stem 
cell markers, SAOS-2 cells, CD133' sorted or unsorted, 
grown in HFB expressed significantly higher levels of the 
markers (see FIG. 5). Specifically, the level of expression of 
these stem cell markers increased between about 20% and 
about 80% in CD133' cells grown in the HFB compared to 
CD133' cells grown under conditions of normal gravity. 
SAOS-2 osteosarcoma cells were seeded into a HFB at a 
concentration of about 6x10 4 cells/mL medium. The rota-
tional speed of the HFB was 25 rpm and the microgravita-
tional force exerted by the HFB was 0.0174 g. The cells were 
grown in an incubator under these conditions: D-MEM 
medium containing 10% FBS, 1 mM L-Glutamine, 100 
U/mL Penicillin, and 100 µg/mL of streptomycin was used at 
37° C. and with 5% CO 2 for 5 days. After 5 days, the cells 
were stained with the described antibodies and processed by 
flow cytometry for expression of the selected markers. 
CD133' enriched SAOS-2 osteosarcoma cells were seeded 
into a HFB at a concentration of 2.5x10 5 cells/mL medium. 
The rotational speed of the HFB was 25 rpm and the micro- 
10 gravitational force exerted by the HFB was 0.0174 g. The 
cells were grown in an incubator under these conditions: 
D-MEM medium containing 10% FBS, 1 mM L-Glutamine, 
100 U/mL Penicillin, and 100 µg/mL of streptomycin was 
used at 37° C. and with 5% CO z for 3 days. After 3 days, the 
15 cells were visualized by microscopy at a magnification of l Ox 
and 40x (FIGS. 6A and 613, respectively) for the presence of 
three-dimensional sarcospheres. The results show that 
CD133' SAOS-2 cells are able to proliferate in the HFB and 
assemble three-dimensionally as sarcospheres (FIG. 6). 
20 CD133' sorted SAOS-2 cells enriched from growth in 
HFB for 3-5 days under the conditions described in Example 
2 were also tested for their ability to attach to culture dishes 
and reconstitute the parent SAOS-2 cell line, by placing 
CD133' sorted SAOS-2 cells grown in HFB (FIGS. 6A and 
25 613) back into adherent cultures (FIGS. 6C and 6D) and visu-
alizing the cells for differentiation at IN and 40x, respec-
tively. 
The results show that CD133' sorted SAOS-2 cells grown 
in HFB are able to reconstitute the parent SAOS-2 line in 
30 adherent dishes after one week in culture in an incubator 
under these conditions: D-MEM medium containing 10% 
FBS, 1 mM L-Glutamine, 100 U/mL Penicillin, and 100 
µg/mL of streptomycin was used at 37° C. and with 5% CO z 
(see FIGS. 6C and 6D). 
35 
Example 7 
CD133' Osteosarcoma Cells Cultured in the HFB 
Proliferate and Upregulate the Expression of 
40 	 Proliferative Markers such as Ki-67 
SAOS-2 cells were grown in the HFB as in Example 2 for 
5 days or in adherent dishes under static conditions for 5 days, 
and their expression of CD133 and the proliferation marker, 
45 Ki-67 were measured by flow cytometry. The proliferation 
marker Ki-67 is expressed when mammalian cells are syn-
thesizing DNA and it is typically used to demonstrate that 
cells are progressing through the S-phase of the cell cycle. 
The results show that compared to SAOS-2 cells grown in 
50 static conditions, a higher proportion of CD133' cells grown 
in HFB also express the proliferation marker Ki-67, showing 
that CD133' cells grown in HFB actually proliferate (see 
FIG. 7). 
55 	 Example 8 
Osteosarcoma Cells Grown in the HFB Display an 
Increase in Telomerase Activity 
60 	 Hos osteosarcoma cells (hTERT positive) were grown in 
HFB as in Example 2 for 5 (FIG. 8, lane 5) or 10 days (FIG. 
8, lane 7) or under static conditions (FIG. 8, lane 3). CD133' 
enriched HOS osteosarcoma cells were seeded into a HFB at 
a concentration of 2.5x10 5 cells/mL medium. The rotational 
65 speed of the HFB was 25 rpm and the microgravitational 
force exertedby the HFB was 0.0174 g. The cells were grown 
in an incubator under these conditions: D-MEM medium 
18 
Example 6 
CD133' Enriched Osteosarcoma Cells Proliferate 
and Assemble into Three-Dimensional Sarcospheres 
5 	 in the HFB 
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containing 10% FBS, 1 mM L-Glutamine, 100 U/mL Peni-
cillin, and 100 ltg/mL of streptomycin was used at 37° C. and 
with 5% COz for 5 or 10 days. 
Telomerase activity in these cells was then measured by 
TRAP assay using the TRAPeze kit (Chemicon, Temecula, 
Calif.). The TRAP assay showed an enhancement of telom-
erase activity in the samples that were grown in HFB for 5 or 
10 days compared to the cells grown in static conditions (see 
FIG. 8). As shown in FIG. 8, the samples cultured for 5 to 10 
days in the HFB show an increased number of total products 
generated (TPG value) (lanes 5 and 7). Each unit of TPG 
(Total Product Generated) corresponds to the number of 
primers used in the reaction (TS primers in 1x10 -3 mole or 
600 molecules) extended with at least 4 telomeric repeats by 
telomerase in the extract in a 30 minute incubation at 30° C. 
The assay has a linear range of 1 to 300 TPG, which is 
equivalent to telomerase activity from approximately 30 to 
10,000 control cells. 
The relative telomerase activity (RTA) level, i.e., the ratio 
between bands corresponding to amplified telomerase prod-
ucts and the internal standard (ITAS) at 0.5 µg protein extract 
was compared with values obtained using TRAP assay and 
the TRAPeze kit (Chemicon, Temecula, Calif.) on series of 
duplicate serial dilutions from individual CHAPS extracts. 
The RTA values of the samples treated with HFB for 5 to 10 
days were higher than the controls. 
Example 9 
Osteosarcoma Cells Grown in HFB Display 
Increased Sensitivity to Cisplatin 
SAOS-2 cells were grown in HFB as in Example 2 for 5 
days, and then harvested. 1x104 cells were plated in 96 well 
dishes and were subjected to 5 (FIG. 913), 10 (FIG. 9C), or 15 
(FIG. 9D) ltg/mL of cisplatin for either 1 or 24 hours and then 
assayed 24 hours later for viability by [3-(4,5-dimethylthi-
azol-2-yl)-2,5-diphenyltetrazolium bromide] "MTT" assay. 
The results show that CD133' cells grown in HFB for 5 days 
were significantly more sensitive to cisplatin compared to 
whole SAOS-2 cultures, or CD133' or CD133 - cells grown 
under normal gravity conditions (see FIG. 9). Specifically, 
CD133' cells were approximately 35, 4 and 15 fold more 
sensitive to cisplatin at the 5, 10 and 15 ltg/mL doses, respec-
tively, compared to resistant CD133' cells grown under nor-
mal gravity conditions. The SAOS-2 cell line was cultured in 
an incubator under these conditions: D-MEM medium con-
taining 10% FBS, 1 mM L-Glutamine, 100 U/mL Penicillin, 
and 100 ltg/mL of streptomycin, at 37° C. and with 5% CO z . 
Example 10 
Osteosarcoma Cells Grown in HFB Display 
Increased Sensitivity to Methotrexate 
SAOS-2 cells were grown in HFB as in Example 2 for 5 
days, and then harvested. 1x104 cells were plated in 96 well 
dishes and were subjected to 4 (FIG. 10B), 11 (FIG. 10C), 22 
(FIG. 10D) or 45 (FIG. 10E) ltg/mL of methotrexate for 1 or 
24 hours and then assayed 24 hours later for viability by MTT 
assay. The results show that CD133' cells grown in HFB for 
5 days were significantly more sensitive to methotrexate com-
pared to whole SAOS-2 cultures, or CD133' or CD133 - cells 
grown under normal gravity conditions (see FIG. 10). Spe-
cifically, CD133' cells were approximately 15, 35, 45 and 60 
fold more sensitive to methotrexate at the 4, 11, 22 and 45 
ltg/mL doses, respectively, compared to resistant CD133' 
cells grown under normal gravity conditions. The SAOS-2 
cell line was cultured in an incubator under these conditions: 
D-MEM medium containing 10% FBS, 1 mM L-Glutamine, 
100 U/mL Penicillin, and 100 ltg/mL of streptomycin, at 37° 
5 C. and with 5% CO z . 
Example 11 
10 	 Osteosarcoma Cells Grown in HFB Display 
Increased Sensitivity to Doxorubicin 
SAOS-2 cells were grown in HFB as in Example 2 for 5 
days, and then harvested. 1 x10 4 cells were plated in 96 well 
15 dishes and were subjected to 0.5 (FIG. 11B), 1.1 (FIG. 11C), 
or 2.5 (FIG. 11D) ltg/mL of doxorubicin for 1 or 24 hours and 
then assayed 24 hours later for viability by MTT assay. The 
results show that CD133' cells grown in HFB for 5 days were 
significantly more sensitive to doxorubicin compared to 
20 whole SAOS-2 cultures, or CD133' or CD133 - cells grown 
under normal gravity conditions (see FIG. 11). Specifically, 
CD133' cells were approximately 1.4, 2, and 2.3 fold more 
sensitive to doxorubicin at the 0.5, 1.1 and 2.5 ltg/mL doses, 
respectively, compared to resistant CD133' cells grown 
25 under normal gravity conditions. The SAOS-2 line was cul-
tured in an incubator under these conditions: D-MEM 
medium containing 10% FBS, 1 mM L-Glutamine, 100 
U/mL Penicillin, and 100 ltg/mL of streptomycin, at 37° C. 
and with 5% COz . 
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Example 12 
The Viability of Osteosarcoma Cells Grown in 
35 	 Normal Gravity (1 G) in the Presence of Omega-3 
Fatty Acids is Decreased 
SAOS-2 cells grown in normal gravity (1G) condition, 
40 containing a mixed population of CD133 (-) and CD133(+) 
cells, were harvested and 1x104 cells were plated in 96 well 
dishes and were treated with 25 or 75 µM of eicosapentaenoic 
acid (MP Biomedicals, Solon, Ohio) for 4 days and then 
assayed 24 hours later for viability by MTT assay. The control 
45 is 75 µM ethanol. The results show that the viability of 
SAOS-2 cells grown in the presence of 75 µM omega-3 fatty 
acids was decreased (see FIG. 12). 
3x105 SAOS-2 cells were plated in 6-well dishes and were 
treated with 25 or 75 µM of eicosapentaenoic acid (MP Bio- 
50 medicals, Solon, Ohio) for 4 days and then assayed 24 hours 
later for Annexin-V. Annexin-V is a cellular protein in the 
annexin group that is used to detect apoptosis. The results 
show that the viability of SAOS-2 cells grown in the presence 
of omega-3 fatty acids in normal gravity was decreased (see 
55 Table 1). Thus, addition of omega-3 fatty acids kills cancer 
cells. 
TABLE 1 
60 	 Percentage of SACS Cells Cultured with Eicosapentaenoic acid 
Early 	 Apoptotic 
Live Apoptotic Necrotic 	 Necrotic 
Control 	 92.4 	 3.9 	 2.5 	 1.2 
25 pM Eicosapentaenoic acid 	 82.7 	 10 	 6.3 	 1 
65 75 pM Eicosapentaenoic acid 	 72.6 	 14.5 	 11.1 	 1.7 
US 8,993,231 B2 
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Example 13 
The Growth of CD133(+) SAOS-2 Cells in the HFB 
is Increased in the Presence of Omega-3 Fatty Acids 
Sixx106 SAOS-2 cells were grown in HFB for 3 days, 
which selected for CD 133 (+) cells, and then 75 µM of eico sa-
pentaenoic acid (MP Biomedicals, Solon, Ohio) or 75 µM of 
ethanol (as a control) were added on day 3 and the cells were 
grown for two more days in HFB. On day 5, cells were 
removed from the HFB, counted and subjected to flow cytom-
etry (99.8% purity). 
TABLE 2 
Cell Count of CD133(+) SACS Cells 
SACS in HFB 	 Cell Count 
+75 pM Eicosapentaenoic acid 	 4,560,000 
+75 pM Ethanol 	 2,280,000 
The results show that SAOS-2 cells grown in HFB in the 
presence of eicosapentaenoic acid grow at a faster rate (see 
Table 2 and FIG. 13). 
Example 14 
The Viability of Cells Grown in HFB in the Presence 
of Omega-3 fatty acids and Cisplatin is Reduced 
Sixx106 SAOS-2 cells were grown in HFB for 3 days, 
which selected for CD 133 (+) cells, and then 75 µM of eico sa-
pentaenoic acid (MP Biomedicals, Solon, Ohio) or 75 µM of 
ethanol (as a control) were added on day 3 and the cells were 
grown for two more days in HFB. On day 5, cells were 
removed from the HFB, counted and subjected to flow cytom-
etry (99.8% purity). Onex104 cells were plated in 96 well 
dishes with or without 5 ltg/mL of Cisplatin and with or 
without 75 ltM of eicosapentaenoic acid for 24 hours. An 
MTT assay was performed in triplicate to assess cell viability 
(see FIG. 14). The cells were also assayed for the presence of 
Annexin-V (see Table 3). 
TABLE 3 
Percentage of viable, apoptotic and necrotic SACS Cells 
Cultured in the HFB with or without Eicosapentaenoic acid 
and with or without Cisplatin 
Early 	 Apoptotic 
Live Apoptotic Necrotic 	 Necrotic 
SACS in HFB 	 49.9 	 35.1 	 13.6 	 1.4 
SACS in HFB + Cisplatin 	 44.1 	 40.4 	 12.7 	 2.8 
SACS in HFB + 	 67.4 	 16 	 8.6 	 7.9 
Eicosapentaenoic acid 
SACS in HFB + Cisplatin + 	 47.1 	 24.8 	 20.7 	 7.4 
Eicosapentaenoic acid 
The results show that CD133 (+) SAOS-2 cells grown in 
HFB in the presence of eicosapentaenoic acid grow at a faster 
rate and display more sensitivity to treatment with cisplatin 
than cells grown in the absence of omega-3 fatty acids. 
What is claimed is: 
1. A method for increasing telomere length in stem cells 
comprising: seeding said stem cells into a Hydrodynamic 
Focusing Bioreactor (HFB), culturing said stem cells under 
conditions allowing for telomere growth, isolating said stem 
cells, and determining the telomere length. 
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2. The method of claim 1 wherein use of said HFB leads to 
a low shear environment with a maximum shear force at 10 
rpm of about 0.01 dyne/cm2 . 
3. The method of claim 1 wherein said telomeres are 
5 lengthened by about 6-24 repeats as compared to stem cells 
grown in normal gravity conditions. 
4. A method for increasing telomerase activity in stem cells 
comprising: seeding said stem cells into a Hydrodynamic 
Focusing Bioreactor (HFB), culturing said stem cells under 
to conditions allowing for increased telomerase activity, isolat-
ing said stem cells, and determining the telomerase activity. 
5. The method of claim 4 wherein use of said HFB leads to 
a low shear environment with a maximum shear force at 10 
rpm of about 0.01 dyne/cm2 . 
15 	 6. A method for increasing the life span of stem cells 
comprising: seeding said stem cells into a Hydrodynamic 
Focusing Bioreactor (HFB), culturing said stem cells under 
conditions allowing for increased life span, isolating said 
stem cells, and determining the telomerase activity in said 
20 stem cells, wherein an increase in telomerase length is indica-
tive of increased life span. 
7. The method of claim 6 wherein the telomeres of said 
stem cells are lengthened. 
8. The method of claim 6 wherein use of said HFB leads to 
25 a low shear environment with a maximum shear force at 10 
rpm of about 0.01 dyne/cm2 . 
9. A method for selectively enriching a stem cell population 
comprising: 
seeding a heterogeneous population of cells into a Hydro- 
30 dynamic Focusing Bioreactor (HFB), the heterogeneous 
population of cells including one or more stem cells and 
one or more differentiated cells; and 
culturing said heterogeneous population of cells under 
microgravity conditions in the HFB for a period of time 
35 sufficient to selectively kill the one or more differenti-
ated cells and selectively enrich the one or more stem 
cells to thereby selectively enrich the stem cell popula-
tion. 
10. The method of claim 9 wherein the microgravitational 
40 force exerted by said HFB is between about 0.01 to about 0.99 
9. 
11. The method of claim 10 wherein the micro gravitational 
force exerted by said HFB is about 0.01 g. 
12. The method of claim 9 wherein the enriched cell popu-
45 lation is CD133+. 
13. The method of claim 9 wherein the enriched cell popu-
lation comprises adult stem cells. 
14. The method of claim 9 wherein the enriched cell popu-
lation comprises cancer stem cells. 
50 	 15. The method of claim 9 wherein said stem cells are 
embryonic stem cells. 
16. The method of claim 9 wherein said stem cells are 
grown at a temperature of about 35° C. to about 39° C. 
17. The method of claim 16 wherein said stem cells are 
55 grown at a temperature of about 37° C. 
18. The method of claim 9 wherein said stem cells are 
cultured in said HFB for about 1 to about 35 days. 
19. The method of claim 18 wherein said stem cells are 
cultured in said HFB for about 7 days. 
60 20. The method of claim 9 wherein said stem cells are 
cultured at an initial concentration of about 0.0005 to about 
1.0x10 6 cells per ml medium. 
21. The method of claim 20 wherein said stem cells are 
cultured at an initial concentration of about 2.5x10 5 cells per 
65 ml medium. 
22. The method of claim 9 wherein the rotational speed of 
said HFB is from about 1 to about 30 rpm. 
US 8,993,231 B2 
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23. The method of claim 22 wherein the rotational speed of 
said HFB is about 25 rpm. 
24. The method of claim 9 wherein said stem cells are 
derived from a cancer patient. 
25. The method of claim 24 wherein said cancerpatient has 
a cancer selected from the group consisting of liquid tumor 
and solid organ tumor. 
26. The method of claim 9 wherein said stem cells are 
derived from a healthy patient. 
27. The method of claim 9 wherein said stem cells are 
genetically modified. 
28. The method of claim 9 wherein use of said HFB leads 
to a low shear environment with a maximum shear force at 10 
rpm of about 0.01 dyne/cm2 . 
29. The method of claim 9 wherein said stem cells are 
cultured in a culture medium comprising from about 0 to 
about 20 percent serum, about 1 mM L-Glutamine, 100 U/mL 
penicillin, and 100 ug/mL Streptomycin. 
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30. A method for culturing stem cells comprising: seeding 
said stem cells into a Hydrodynamic Focusing Bioreactor 
(HFB) and culturing said stem cells under conditions allow-
ing for telomere growth. 
5 	 31. A method for culturing stem cells comprising: seeding 
said stem cells into a Hydrodynamic Focusing Bioreactor 
(HFB) and culturing said stem cells under conditions allow-
ing for increased telomerase activity. 
32. A method for culturing stem cells comprising: seeding 
said stem cells into a Hydrodynamic Focusing Bioreactor 
10 (HFB) and culturing said stem cells under conditions allow-
ing for increased life span. 
33. A method for proliferating cancer cells comprising 
seeding cancer cells into a Hydrodynamic Focusing Bioreac- 
15 for (HFB) culturing said cancer cells, and allowing said can-
cer cells to form into cancerous tissue. 
34. The method of claim 33 wherein said cancer cells are 
cultured in the presence of omega-3 fatty acids. 
